Switch theme
Sign up to access all valuation multiples
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
2013
244
LTM Revenue $74.7M
LTM EBITDA -$164M
-$274M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alector has a last 12-month revenue of $74.7M and a last 12-month EBITDA of -$164M.
In the most recent fiscal year, Alector achieved revenue of $101M and an EBITDA of -$136M.
Alector expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alector valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $97.1M | $101M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$143M | -$136M | XXX | XXX | XXX |
| EBITDA Margin | -147% | -135% | XXX | XXX | XXX |
| Net Profit | -$133M | -$130M | XXX | XXX | XXX |
| Net Margin | -137% | -130% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alector's stock price is $1.
Alector has current market cap of $97.2M, and EV of -$274M.
See Alector trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$274M | $97.2M | XXX | XXX | XXX | XXX | $-1.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alector has market cap of $97.2M and EV of -$274M.
Alector's trades at -3.7x LTM EV/Revenue multiple, and 1.7x LTM EBITDA.
Analysts estimate Alector's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alector and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$274M | XXX | XXX | XXX |
| EV/Revenue | -2.7x | XXX | XXX | XXX |
| EV/EBITDA | 2.0x | XXX | XXX | XXX |
| P/E | -0.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlector's NTM/LTM revenue growth is -70%
Alector's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Alector's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alector's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alector and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -135% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -206% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 59% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 185% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 244% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alector acquired XXX companies to date.
Last acquisition by Alector was XXXXXXXX, XXXXX XXXXX XXXXXX . Alector acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alector founded? | Alector was founded in 2013. |
| Where is Alector headquartered? | Alector is headquartered in United States of America. |
| How many employees does Alector have? | As of today, Alector has 244 employees. |
| Who is the CEO of Alector? | Alector's CEO is Dr. Arnon Rosenthal, PhD. |
| Is Alector publicy listed? | Yes, Alector is a public company listed on NAS. |
| What is the stock symbol of Alector? | Alector trades under ALEC ticker. |
| When did Alector go public? | Alector went public in 2019. |
| Who are competitors of Alector? | Similar companies to Alector include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alector? | Alector's current market cap is $97.2M |
| What is the current revenue of Alector? | Alector's last 12-month revenue is $74.7M. |
| What is the current EBITDA of Alector? | Alector's last 12-month EBITDA is -$164M. |
| What is the current EV/Revenue multiple of Alector? | Current revenue multiple of Alector is -3.7x. |
| What is the current EV/EBITDA multiple of Alector? | Current EBITDA multiple of Alector is 1.7x. |
| What is the current revenue growth of Alector? | Alector revenue growth between 2023 and 2024 was 4%. |
| Is Alector profitable? | Yes, Alector is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
